Jacobs Levy Equity Management Inc. Boosts Stock Position in biote Corp. (NASDAQ:BTMD)

Jacobs Levy Equity Management Inc. lifted its holdings in shares of biote Corp. (NASDAQ:BTMD) by 24.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 272,377 shares of the company’s stock after buying an additional 54,302 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.50% of biote worth $1,520,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in biote by 251.8% during the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after purchasing an additional 138,200 shares in the last quarter. Wasatch Advisors LP lifted its stake in biote by 8.4% in the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after buying an additional 107,792 shares in the last quarter. Bailard Inc. acquired a new stake in biote in the 2nd quarter worth about $146,000. The Manufacturers Life Insurance Company purchased a new stake in biote during the 2nd quarter worth approximately $84,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of biote by 59.0% during the second quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after acquiring an additional 34,999 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Price Performance

Shares of NASDAQ:BTMD opened at $6.43 on Monday. biote Corp. has a 1 year low of $3.65 and a 1 year high of $8.44. The firm has a market capitalization of $349.41 million, a PE ratio of 24.73 and a beta of 1.07. The business’s 50 day moving average price is $5.69 and its 200-day moving average price is $6.34.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.